Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 3/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352723 | 0.98 | ACP3 (0.46) | ACP3HRH1POLBCYP2D6SRC | |
| Hydrochloric Acid SCHEMBL2392993 | 0.97 | ACP3 (0.45) | ACP3HRH1POLBCYP2D6SRC | |
| SCHEMBL2354091 | 0.86 | ACP3 (0.44) | ACP3HRH1POLBCYP2D6 | |
| SCHEMBL2408233 | 0.85 | ACP3 (0.46) | ACP3POLBCYP2D6SRC | |
| SCHEMBL2172503 | 0.83 | ACP3 (0.47) | ACP3POLBCYP2D6SRC | |
| SCHEMBL2354039 | 0.83 | GABBR2 (0.45) | ACP3HRH1POLBCYP2D6 | |
| SCHEMBL2352708 | 0.83 | ACP3 (0.44) | ACP3HRH1CYP2D6ANPEP | |
| SCHEMBL31315617 | 0.81 | ACP3 (0.50) | ACP3POLBCYP2D6SRC | |
| Hydrogen Peroxide SCHEMBL8609521 | 0.81 | ACP3 (0.50) | ACP3POLBCYP2D6SRC | |
| SCHEMBL2352039 | 0.79 | ACP3 (0.46) | ACP3HRH1POLBSRCHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213061-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213061-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof | HAO2, ACSL1, ACSL3 | ACP3 970/4885HRH1 328/4885POLB 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.